lysosomal storage disease

January 2005
Taber's Cyclopedic Medical Dictionary;2005, p1285
Reference Entry
A definition of the medical term "lysosomal storage disease" is presented. This term denotes a disorder that is caused by the lack of lysosomal enzymes that normally degrade glycolipids, glycoproteins or mucopolysaccharides. The definition is from the "Taber's Cyclopedic Medical Dictionary," published by F.A. Davis Co.The pronunciation of the term is also provided.


Related Articles

  • iron storage disease.  // Taber's Cyclopedic Medical Dictionary;2005, p1142 

    A definition of the medical term "iron storage disease" is presented. It refers to hemochromatosis. The definition is from the "Taber's Cyclopedic Medical Dictionary," published by F.A. Davis Co.

  • I cell disease.  // Taber's Cyclopedic Medical Dictionary;2005, p1062 

    A definition of the term "I cell disease" is presented, which refers to mucolipidosis type II.

  • mucolipidosis.  // Taber's Cyclopedic Medical Dictionary;2005, p1394 

    A definition of the medical term "mucolipidosis" is presented. It refers to the inherited lysosomal storage diseases in which abnormalities in the transport of lysosomal enzymes into lysosomes result in their accumulation in extracellular fluids or plasma. The definition is from the "Taber's...

  • Continuing Education Test #1140.  // RN;Jul2008, Vol. 71 Issue 7, p38 

    A quiz about lysosomal storage diseases is presented.

  • Glucuronidase deficiency disease.  // Taber's Cyclopedic Medical Dictionary;2005, p892 

    A definition of the term "Glucuronidase deficiency disease" is presented, which means Mucopolysaccharidosis VII.

  • Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice Liu, Yuli; Xu, Lingfei; Hennig, Anne K.; Kovacs, Attila; Fu, Annabel; Chung, Sarah; Lee, David; Wang, Bin; Herati, Ramin S.; Mosinger Ogilvie, Judith; Cai, Shi-Rong; Parker Ponder, Katherine // Molecular Therapy;Jan2005, Vol. 11 Issue 1, p35 

    Abstract: Mucopolysaccharidosis I (MPS I) due to deficient α-l-iduronidase (IDUA) activity results in accumulation of glycosaminoglycans in many cells. Gene therapy could program liver to secrete enzyme with mannose 6-phosphate (M6P), and enzyme in blood could be taken up by other cells via...

  • Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Cheng, S H; Smith, A E // Gene Therapy;Aug2003, Vol. 10 Issue 16, p1275 

    Despite disappointments with early clinical studies, there is continued interest in the development of gene therapy for the group of metabolic diseases referred to as lysosomal storage disorders (LSDs). The LSDs are monogenic and several small and large, representative animal models of the human...

  • ENZYME REPLACEMENT THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE VI (MAROTEAUX--LAMY SYNDROME). Beck, Michael // Current Medical Literature: Lysosomal Storage Disease;2005, Vol. 5 Issue 2, p20 

    Discusses the results of the study on the application of enzyme replacement therapy in mucopolysaccharidosis type IV, a rare lysosomal storage disorder with multiple organ and tissue involvement. Decrease of glycosaminoglycan excretion in treated patients; Improvement of the walking distance in...

  • Fabry or No Fabry: A Case Report. Linthorst, Gabor E.; Vedder, Anouk C.; Hollak, Carla E,. M. // Current Medical Literature: Lysosomal Storage Disease;2007, Vol. 7 Issue 3, p67 

    The article discusses the medical case of two patients with Anderson-Fabry disease (AFD), a lysosomal storage disorder (LSD) resulting from α-galactosidase A (α-gal A) deficiency. The two patients had different symptoms associated with AFD. Patient A had reduced leukocyte α-gal A...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics